We are live on ! Find out more

Elicio Therapeutics

ELTX

Market cap $40.9M

1.51 USD

+0.11

7.86%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

1.48

-0.03

1.99%

1 day

7.86%

5 days

-13.71%

1 month

-19.68%

3 months

-51.91%

6 months

-85.55%

Year to date

-81.24%

1 year

-83.35%

5 years

-96.9%

10 years

-99.11%

About: Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Employees: 33

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported financial results for the quarter ended September 30, 2026, and provided recent corporate and clinical updates.

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.

Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer's (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.

Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-breaking Proffered Paper oral session at the European Society for Medical Oncology (“ESMO”) Congress 2026 in Madrid, Spain, and simultaneously published in Nature Medicine: "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial".

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic ductal adenocarcinoma (“PDAC”) have been selected for a late-breaking Proffered Paper oral presentation at the European Society for Medical Oncology (“ESMO”) Congress 2026, being held October 23–27, 2026, in Madrid, Spain.

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

See News Rankings

Price charts implemented using Lightweight Charts™